The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Vitamin D receptor has antiproliferative effects in pulmonary arterial hypertension, but receptor expression is downregulated ...

A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain ...

Effective July 1, 2025, this agreement ensures that nearly 400,000 patients covered by IBX each year will keep receiving quality care from Penn Medicine providers. The partnership focuses on improving ...